This document is a published patent application from the USPTO, specifically application US20260085319A1, filed on August 26, 2025. It describes compositions and methods for treating CHD2 haploinsufficiency by increasing the amount of CHD2 protein in neuronal cells using a nucleic acid agent directed at the last exon of human Chaserr.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future intellectual property and market exclusivity for novel treatments in this area. Companies involved in biotechnology, pharmaceuticals, and neurological treatments should monitor the progress of this application and related patents, as they may impact research and development strategies and market entry for therapies targeting CHD2 haploinsufficiency.